Lee JH, Choi J, Min C-K, Park S-S, Jo J-C, Lee YJ, Kim JS, Eom H-S, Jung J, Moon JH, Cho HJ, Lee M- won, Yoon S-S, Byun JM, Lee JH, Lee J-J, Jung S-H, Shin H-J, Kim DY, Yi JH, Lee S-S, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim S-H, Kim K. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study. haematol [Internet]. 2020Sep.10 [cited 2024Jul.16];. Available from: https://haematologica.org/article/view/haematol.2024.285534